戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ous system (CNS) and may provide targets for therapeutic angiogenesis.
2 a strategy to improve safety and efficacy of therapeutic angiogenesis.
3 ological clinical conditions has been called therapeutic angiogenesis.
4 first growth factors to be tested for use in therapeutic angiogenesis.
5 ffect of progenitor cell transplantation for therapeutic angiogenesis.
6 blood vessels is critical for the success of therapeutic angiogenesis.
7 This hypothesis was tested in the context of therapeutic angiogenesis.
8  cell therapy have moved to the forefront of therapeutic angiogenesis.
9 as emerged as one of principal approaches to therapeutic angiogenesis.
10 ulating interest in their ability to mediate therapeutic angiogenesis.
11 e strategy to robustly boost the efficacy of therapeutic angiogenesis.
12 indings suggest a potential role for PEMF in therapeutic angiogenesis.
13 cacy of revascularization strategies such as therapeutic angiogenesis.
14 y provide a noninvasive method for assessing therapeutic angiogenesis.
15 healing, and which is a potential target for therapeutic angiogenesis.
16 r to avoid the formation of leaky vessels in therapeutic angiogenesis.
17 us angiogenic factors, might provide optimal therapeutic angiogenesis.
18 provide a more effective strategy to achieve therapeutic angiogenesis.
19 is system was investigated in the context of therapeutic angiogenesis.
20 endothelial cell mitogen designed to promote therapeutic angiogenesis.
21 chnique may be useful in clinical studies of therapeutic angiogenesis.
22 gs are consistent with a favorable effect of therapeutic angiogenesis.
23 importance of regulating VEGF expression for therapeutic angiogenesis.
24 sues is a potential cause for the failure of therapeutic angiogenesis.
25 lone or in combination with VEGF, to promote therapeutic angiogenesis.
26 osis and vein graft intimal hyperplasia, and therapeutic angiogenesis.
27  for stimulating endothelial cell-autologous therapeutic angiogenesis.
28                                              Therapeutic angiogenesis, a new experimental strategy fo
29                                           In therapeutic angiogenesis, an angiogen--a mediator that i
30 formation might lead to novel approaches for therapeutic angiogenesis and arteriogenesis for PAD.
31 ser revascularization (TMR) for induction of therapeutic angiogenesis and arteriogenesis in the chron
32  vasculature can help realize the promise of therapeutic angiogenesis and tissue engineering.
33 nd mouse, which gives insight of VEGF165b in therapeutic angiogenesis and VEGF distribution in human
34 ollateral vessel growth to ischemic tissues (therapeutic angiogenesis) and for delivering anti- or pr
35  endothelial growth factor (VEGF) to promote therapeutic angiogenesis are under consideration for con
36                    This review is focused on therapeutic angiogenesis based on gene transfer strategi
37                                              Therapeutic angiogenesis by delivery of vascular growth
38 ings of TRAFFIC provide evidence of clinical therapeutic angiogenesis by intra-arterial infusion of a
39 he recently reported approaches to stimulate therapeutic angiogenesis by recreating the embryonic vas
40  CD34Exo-mediated ischemic tissue repair and therapeutic angiogenesis by studying their miRNA content
41                                              Therapeutic angiogenesis by the administration of recomb
42                           Clinical trials of therapeutic angiogenesis by vascular endothelial growth
43                                              Therapeutic angiogenesis describes a novel approach to t
44 dicate that CARP could play a unique role in therapeutic angiogenesis during wound healing.
45                Treatment of ischemia through therapeutic angiogenesis faces significant challenges.
46 ngiogenesis 30 days later showed evidence of therapeutic angiogenesis for both pcVEGF-C and rhVEGF-C.
47 nsus on the challenges facing development of therapeutic angiogenesis for coronary disease.
48                      These data suggest that therapeutic angiogenesis for ischemic cardiovascular dis
49 s angiogenesis in two animal models in which therapeutic angiogenesis has been characterized as a com
50   To address this unmet need, the science of therapeutic angiogenesis has been evolving for almost tw
51 l trials including VEGF-A administration for therapeutic angiogenesis have not been successful.
52                             Animal models of therapeutic angiogenesis have stimulated development of
53                                              Therapeutic angiogenesis holds great potential for a myr
54                                     Although therapeutic angiogenesis holds great promise for treatin
55 mitant delivery or single VEGF delivery, for therapeutic angiogenesis in chronic ischemia.
56  that CD34(+) cells may be a useful tool for therapeutic angiogenesis in diabetics.
57 owth factor (VEGF) is being investigated for therapeutic angiogenesis in ischemic myocardium.
58 issue affinity may be potentially useful for therapeutic angiogenesis in ischemic tissues.
59 repancy exists between the potent effects of therapeutic angiogenesis in laboratory animals and the m
60  cardiac apoptosis and fibrosis by promoting therapeutic angiogenesis in mice with MI.
61 dothelial growth factor (VEGF) treatment for therapeutic angiogenesis in myocardial ischemia, we expl
62   In addition, preliminary results on use of therapeutic angiogenesis in patients with Buerger's dise
63 t an alternative to VEGF-A for strategies of therapeutic angiogenesis in patients with limb and/or my
64  overexpression of VEGF sufficient to induce therapeutic angiogenesis in selected patients with criti
65 linical trials that had the goal of inducing therapeutic angiogenesis in the ischemic heart and in th
66 but the impact of endothelial dysfunction on therapeutic angiogenesis in the myocardium has been uncl
67 (VEGF) 121 cDNA (Ad(GV)VEGF121.10) to induce therapeutic angiogenesis in the myocardium of individual
68 ssue regeneration, supporting the concept of therapeutic angiogenesis in tissue-engineering strategie
69 firm the feasibility of a novel approach for therapeutic angiogenesis in which neovascularization may
70 ction that tumor ischemia should result from therapeutic angiogenesis inhibition, tumor cell hypoxia
71 D 173074 is thus a promising candidate for a therapeutic angiogenesis inhibitor to be used in the tre
72                                              Therapeutic angiogenesis is a new approach to treating i
73                                     Although therapeutic angiogenesis is an attractive option for the
74                                              Therapeutic angiogenesis is an emerging paradigm for the
75                                              Therapeutic angiogenesis is an exciting field that conti
76                                              Therapeutic angiogenesis is an investigational method th
77  the underlying mechanism for AGGF1-mediated therapeutic angiogenesis is unknown.
78 mic tissues using angiogenic growth factors (therapeutic angiogenesis) is a an exciting frontier of c
79 ong-term constitutive expression of VEGF for therapeutic angiogenesis may be limited by the growth of
80                       The ability to promote therapeutic angiogenesis may be limited in diabetes.
81 e transfer with ZFP-VEGF was able to promote therapeutic angiogenesis mice with type 2 diabetes.
82 have been tremendous changes in the field of therapeutic angiogenesis over the past decade, and there
83                                              Therapeutic angiogenesis (promoting new vessel growth to
84                                              Therapeutic angiogenesis represents a promising treatmen
85                                              Therapeutic angiogenesis seeks to promote blood vessel g
86                                             "Therapeutic angiogenesis" seeks to improve perfusion by
87 roup of nonpeptide molecules that can induce therapeutic angiogenesis, such as in wound healing.
88 nt of collateral arteries, a concept called "therapeutic angiogenesis." The objectives of this phase
89  Gene transfer is a novel means of providing therapeutic angiogenesis: the cDNA coding for specific a
90 hat (1) autophagy is essential for effective therapeutic angiogenesis to treat CAD and MI; (2) AGGF1
91 duration of gene expression investigated for therapeutic angiogenesis transfer have been unassociated
92 uring, and after adjuvant antiangiogenic and therapeutic angiogenesis treatments.
93 lying mechanisms involved in physiologic and therapeutic angiogenesis, underscoring the relative impo
94 nical stage, experimental data indicate that therapeutic angiogenesis using short-term gene expressio
95 lastin-like Polypeptide (ELP-VEGF) to induce therapeutic angiogenesis via targeted renal VEGF therapy
96 vascular endothelial growth factor (VEGF) in therapeutic angiogenesis was suggested by experiments in
97 rdial perfusion; however, further studies of therapeutic angiogenesis with Ad5FGF-4 will be necessary
98                                              Therapeutic angiogenesis would be clinically valuable in
99                                              Therapeutic angiogenesis would re-establish blood perfus